Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/5/2024 | $8.00 | Buy | Craig Hallum |
| 8/28/2024 | Outperform → Mkt Perform | Barrington Research | |
| 3/20/2023 | $11.00 → $2.00 | Overweight → Equal-Weight | Stephens |
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it hosted a virtual investor day prior to market open during which Lifecore's senior management team discussed the company's business and strategy for growth in the future, among other topics. A replay of the event is available via webcast and can be accessed by visiting the Events & Presentations section of Lifecore's investor web page at: https://ir.lifecore.com/events-presentations. About Lifecore Biomedical Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a fully integrated contract deve
CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that Paul Josephs, the company's president and chief executive officer, will be a featured speaker in a fireside chat at the upcoming Stephens Annual Investment Conference. The conference is being held November 19-21, 2024, in Nashville, Tennessee. Details regarding Lifecore's participation are as follows: Stephens Annual Investment ConferenceDetails: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in 1-on-1 meetingsConference Dates: Novembe
CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 – 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore's senior management team will discuss the company's business and strategy for growth in the future, among other topics. To listen to the live webcast, or access the archived webcast, please visit the Events & Presentations section of Lifecore's investor web page at: https:
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
424B3 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity Jackie Klecker Named Executive Vice President, Quality and Development Services to Focus on Sustaining Company's Strong Regulatory and Compliance Track Record Personnel Moves Bifurcate Operations and Quality Functions to Align with Company's Growth Strategy and Reflect Natural Evolution of Business CHASKA, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Thomas Guldager as vice president, operations. An
WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p
CHASKA, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced the appointment of Brikkelle Thompson as senior vice president of human resources. Ms. Thompson brings nearly 25 years of visionary human resources leadership, global experience, and deep talent management to Lifecore, including 14 years in the medical technology, medical device, and healthcare industries. She will be charged with enhancing the company's performance-driven culture, while further strengthening the Lifecore team by maintaining and securing exceptional talent.
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
Craig Hallum initiated coverage of Lifecore Biomedical with a rating of Buy and set a new price target of $8.00
Barrington Research downgraded Lifecore Biomedical from Outperform to Mkt Perform
Stephens downgraded Lifecore Biomedical from Overweight to Equal-Weight and set a new price target of $2.00 from $11.00 previously
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
- SEC Filing
Lifecore Biomedical, Inc. (NASDAQ:LFCR) (the "Company") announced today that, on April 15, 2024, the Company received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the "Q3 Form 10-Q") and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the "Q1 Form 10-Q" and "Q2 Form 10-Q," respectively, and together with the Q3 Form 10-Q, the "Filings") with the Securities and Exchange Commission (the "SEC
-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers -- -- More than Doubled Capacity with Installation of 5-Head Isolator Filler; Increased Revenue Generating Potential to Up to $300 Million Annually -- -- Successfully Closed Financing Raising Approx. $24.3 Million, Providing Financial Runway for Current Liquidity Needs and Future Growth -- Conference Call Today at 8:30 a.m. ET CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financia
-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% ---- High Value Pipeline Continues to Advance Toward Commercialization ---- State-of-the-Art Technology Enhancements to Expand Capacityand New Business Opportunities – Conference Call Tomorrow Morning at 8:30 a.m. ET CHASKA, Minn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financial results for the fourth quarter and full year of fiscal 2024. Highlights from Fiscal 2024: "Operationally, fiscal 2024 was a strong year for the Company as we
Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board Chair CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis. Board Concludes it